Modality
Vaccine
MOA
CD47i
Target
WRN
Pathway
Ferroptosis
SCD
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
→ Dec 2031
Phase 1Current
NCT08983023
1,331 pts·SCD
2022-08→2026-05·Recruiting
NCT08928742
722 pts·SCD
2024-01→2031-12·Active
2,053 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-262mo awayInterim· SCD
2031-12-065.7y awayInterim· SCD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
P1
Active
Catalysts
Interim
2026-05-26 · 2mo away
SCD
Interim
2031-12-06 · 5.7y away
SCD
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Lisorapivir | Takeda | Preclinical | WRN |